Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion criteria:~* Participant must be 18 to 55 years of age, inclusive, at the time of signing the informed consent.~* Participant was diagnosed with relapsing multiple sclerosis (RMS) according to the 2017 revision of the McDonald diagnostic criteria.~* Participant must had at least 1 documented relapse within the previous year, OR greater than or equal to (\>=) 2 documented relapses within the previous 2 years, OR \>=1 active Gadolinium (Gd) enhancing brain lesion on an MRI scan in the past 6 months and prior to screening.~* A female participant must had used a double contraception method including a highly effective method of birth control from inclusion and up to 2 months after the last study dose, except if she had undergone sterilization at least 3 months earlier or was postmenopausal. Menopause was defined as being amenorrheic for \>=12 months with serum follicle-stimulating hormone (FSH) level greater than (\>) 30 International Units per liters.~* Male participants, whose partners were of childbearing potential (including breastfeeding women), must had accepted to use, during sexual intercourse, a double contraceptive method according to the following algorithm: (condom) plus (intrauterine device or hormonal contraceptive) from inclusion up to 3 months after the last dose.~* Male participants whose partners were pregnant must had used, during sexual intercourse, a condom from inclusion up to 3 months after the last dose.~* Male participants had agreed not to donate sperm from the inclusion up to 3 months after the last dose.~* Participant had given written informed consent prior to undertaking any study-related procedure.~Exclusion criteria:~* The participant had been diagnosed with primary progressive multiple sclerosis according to the 2017 revision of the McDonald diagnostic criteria or with non relapsing secondary progressive multiple sclerosis.~* Requirement for concomitant treatment that could bias the primary evaluation.~* Contraindication for MRI.~* Contraindications to use MRI Gd contrast-enhancing preparations.~* History of infection with the human immunodeficiency virus (HIV).~* History of active or latent tuberculosis.~* Any other active infections that would adversely affect participation or investigational medicinal product administration in this study, as judged by the Investigator.~* Presence of any screening laboratory or electrocardiogram values outside normal limits that were considered in the Investigator's judgment to be clinically significant.~* Presence of liver injury.~* At screening, the participant was positive for hepatitis B surface antigen and/or hepatitis B core antibody and/or was positive for hepatitis C antibody.~* Bleeding disorder or known platelet dysfunction at any time prior to screening visit.~* Participant had received any live (attenuated) vaccine (including but not limited to varicella zoster, oral polio, and nasal influenza) within 2 months before first treatment visit.~* Participant was receiving strong inducers or inhibitors of cytochrome P450 3A (CYP3A) or CYP2C8 hepatic enzymes.~* Participant was receiving anticoagulant/antiplatelet therapies.~* Participant had taken other investigational drugs within 3 months or 5 half lives, whichever was longer, before screening visit.~* Participant had an Expanded Disability Status Scale score \>5.5 at first screening visit.~* Participant had a relapse in the 30 days prior to randomization.~* Participant was pregnant or a breastfeeding woman.~* History or presence of significant other concomitant illness.~* The participant had received medications/treatments for multiple sclerosis within a specified time frame.~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1: SAR442168 5 mg Then Placebo (Type: EXPERIMENTAL): Participants received SAR442168 5 milligrams (mg), orally once daily for first 12 weeks then crossed over to matching placebo orally once daily for 4 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
- Cohort 1: SAR442168 15 mg Then Placebo (Type: EXPERIMENTAL): Participants received SAR442168 15 mg, orally once daily for first 12 weeks then crossed over to matching placebo orally once daily for 4 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
- Cohort 1: SAR442168 30 mg Then Placebo (Type: EXPERIMENTAL): Participants received SAR442168 30 mg, orally once daily for first 12 weeks then crossed over to matching placebo orally once daily for 4 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
- Cohort 1: SAR442168 60 mg Then Placebo (Type: EXPERIMENTAL): Participants received SAR442168 60 mg, orally once daily for first 12 weeks then crossed over to matching placebo orally once daily for 4 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
- Cohort 2: Placebo Then SAR442168 5 mg (Type: EXPERIMENTAL): Participants received placebo matching to SAR442168 tablets, orally once daily for first 4 weeks then crossed over to SAR442168 5 mg orally once daily for 12 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
- Cohort 2: Placebo Then SAR442168 15 mg (Type: EXPERIMENTAL): Participants received placebo matching to SAR442168 tablets, orally once daily for first 4 weeks then crossed over to SAR442168 15 mg orally once daily for 12 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
- Cohort 2: Placebo Then SAR442168 30 mg (Type: EXPERIMENTAL): Participants received placebo matching to SAR442168 tablets, orally once daily for first 4 weeks then crossed over to SAR442168 30 mg orally once daily for 12 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
- Cohort 2: Placebo Then SAR442168 60 mg (Type: EXPERIMENTAL): Participants received placebo matching to SAR442168 tablets, orally once daily for first 4 weeks then crossed over to SAR442168 60 mg orally once daily for 12 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.

Based on this trial design, predict the completion outcome and termination type (if applicable).